Kalaris Therapeutics Q3 2026 Results: Net Loss of $11M, Loss Narrows
Kalaris Therapeutics, Inc. (formerly AlloVir, Inc.) is a clinical-stage biotechnology company focused on its lead product candidate, TH103. The company has incurred significant losses since inception, expects continued operating losses for the foreseeable future, and recently completed a merger with AlloVir.
- Key figure
- Net loss $11M